Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Abstract Background In clinical trials, poly (ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy resulted in significantly improved progression-free survival, manageable adverse event profiles, and favorable patient-reported outcomes (PROs) in patients with human epidermal growth factor r...

Full description

Bibliographic Details
Main Authors: Reshma Mahtani, Alexander Niyazov, Bhakti Arondekar, Katie Lewis, Alex Rider, Lucy Massey, Michael Patrick Lux
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
Advanced breast cancer
BRCA1/2 mutation
Chemotherapy
Patient-reported outcomes
Poly (ADP-ribose) polymerase inhibitors
Quality of life
Online Access:https://doi.org/10.1186/s12885-022-10325-9

Internet

https://doi.org/10.1186/s12885-022-10325-9

Similar Items